If you have been reading about tissue repair and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-09. Numbers and descriptions here follow the published literature rather than marketing material.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
The maximum yield in such kinetic resolutions is 50%, since a yield of more than 50% means that some of wrong isomer also has reacted, giving a lower enantiomeric excess. Such reactions must therefore be terminated before equilibrium is reached. If it is possible to perform such resolutions under conditions where the two substrate- enantiomers are racemizing continuously, all substrate may in theory be converted into enantiopure product. This is called dynamic resolution. In biocatalyzed asymmetric synthesis, a non-chiral unit becomes chiral in such a way that the different possible stereoisomers are formed in different quantities. The chirality is introduced into the substrate by influence of enzyme, which is chiral. Yeast is a biocatalyst for the enantioselective reduction of ketones.
=== Sulfhydryl-containing agents === Alacepril Captopril (trade name Capoten), the first ACE inhibitor. Zofenopril These agents appear to show antioxidative properties but may be involved in adverse events such as skin eruptions.
== Peptide hormones == Kaufmann and Brown 2008 find the An. gambiae adipokinetic hormone (AKH) mobilizes carbohydrates but not lipids. Meanwhile AKH/Corazonin Peptide (ACP) does not mobilize (or inhibit mobilization) of either. Mugumbate et al., 2013 provides in solution and membrane bound structures from a nuclear magnetic resonance investigation.
Sources: en.wikipedia.org
1 On 27 April 2010, Troy Buswell resigned from the ministry following questions arising from a personal affair with Greens MP Adele Carles. The following day, Premier Colin Barnett assumed the role of Treasurer, while Buswell's remaining portfolios were transferred to Bill Marmion, who had hitherto been a parliamentary secretary.
Research into how vitamin E prevents the process of lipid peroxidation led to the identification of antioxidants as reducing agents that prevent oxidative reactions, often by scavenging ROS before they can damage cells.
==== MeSH E05.181.724 – ultracentrifugation ==== MeSH E05.181.724.336 – centrifugation, density gradient MeSH E05.181.724.336.253 – centrifugation, isopycnic MeSH E05.181.724.336.336 – centrifugation, zonal
Sources: en.wikipedia.org
== Cause == There are two genetic traits linked to feline cutaneous asthenia. One comes from a dominant allele, while the other comes from a recessive. Both result in similar pathology. Cats with the autosomal dominant form of feline cutaneous asthenia package type I collagen poorly. Collagen is a major component in skin tissue and in tendons. While scientists originally suspected that the problem lay in the production of the type I collagen molecule, it is now known that type V collagen is the molecule which is incorrectly produced. Although scientists do not know exactly how, many suspect that type V collagen assists in packaging type I collagen. Collagen fibrils are often abnormally sized and have unusually large amounts of space between them. The dermis is thinned because of this. In heterozygous cats, normal and abnormal fibrils often exist inside of the same collagen fiber. Homozygous cats are not likely to survive for very long. The autosomal recessive form of feline cutaneous asthenia results in a deficiency of procollagen peptidase or a structural abnormality at its cleavage site. Procollagen peptidase is an enzyme necessary for the post-translational modification of procollagen into collagen. Because of the abnormalities in the formation of collagen fibrils, affected cats produce twisted collagen ribbons, rather than the normal collagen cylinders one would expect to find.
=== The Middle === Shaffer is most known for his role as Brick Heck in The Middle, which he played throughout the series' entire nine-season run, from 2009 to 2018. In a Wired magazine interview published in January 2013, Shaffer said his role as Brick was similar to his own life, as he is also a "big reader" and "nerd[s] out over the weirdest stuff". In May 2011, a TV Guide article had reported the closeness as well. Brick's characterization, including his idiosyncratic palilalian repetition of words and phrases at the end of sentences, is based on Justin Heisler, the son of The Middle co-creator Eileen Heisler.
=== Other inorganic compounds === The pnictides of berkelium-249 of the type BkX are known for the elements nitrogen, phosphorus, arsenic and antimony. They crystallize in the rock-salt structure and are prepared by the reaction of either berkelium(III) hydride (BkH3) or metallic berkelium with these elements at elevated temperature (about 600 °C) under high vacuum. Berkelium(III) sulfide, Bk2S3, is prepared by either treating berkelium oxide with a mixture of hydrogen sulfide and carbon disulfide vapors at 1130 °C, or by directly reacting metallic berkelium with elemental sulfur. These procedures yield brownish-black crystals. Berkelium(III) and berkelium(IV) hydroxides are both stable in 1 molar solutions of sodium hydroxide. Berkelium(III) phosphate (BkPO4) has been prepared as a solid, which shows strong fluorescence under excitation with a green light. Berkelium hydrides are produced by reacting metal with hydrogen gas at temperatures about 250 °C. They are non-stoichiometric with the nominal formula BkH2+x (0 < x < 1). Several other salts of berkelium are known, including an oxysulfide (Bk2O2S), and hydrated nitrate (Bk(NO3)3·4H2O), chloride (BkCl3·6H2O), sulfate (Bk2(SO4)3·12H2O) and oxalate (Bk2(C2O4)3·4H2O). Thermal decomposition at about 600 °C in an argon atmosphere (to avoid oxidation to BkO2) of Bk2(SO4)3·12H2O yields the crystals of berkelium(III) oxysulfate (Bk2O2SO4). This compound is thermally stable to at least 1000 °C in inert atmosphere.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.